Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS (Details)

v3.24.3
COMMITMENTS (Details)
3 Months Ended 9 Months Ended
Jan. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Mar. 08, 2024
USD ($)
site
Feb. 01, 2024
Dec. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Long-term Purchase Commitment [Line Items]                  
Operating lease, prior notice for cancellation 1 month                
Monthly rent expense $ 1,800                
Lease commenced, initial period             3 years    
Rent expense   $ 5,400 $ 4,000 $ 15,840 $ 12,000        
Research and development   2,893,000 1,623,000 8,165,000 4,788,000        
Accrued liabilities   1,856,000   1,856,000       $ 1,194,000  
Triple Ring Technologies                  
Long-term Purchase Commitment [Line Items]                  
Purchase commitments                 $ 1,700,000
Research and development   100,000 $ 300,000 300,000 $ 800,000        
Remaining commitment   100,000   100,000          
Clinical Research Organization                  
Long-term Purchase Commitment [Line Items]                  
Research and development   100,000   700,000          
Remaining commitment   100,000   100,000          
Amount to be paid to clinical research organization (CRO)           $ 500,000      
Number of planned sites to carrying out the clinical study | site           5      
Research and development expense, expected cost           $ 900,000      
Accrued liabilities   $ 100,000   $ 100,000